RAD-208

N/A

Report date: 2025/09/10 14:02:49

Base Information

Drug NameRAD-208

Drug Alias NameRAD-208

ClassificationRadiation-emitting products > Radioactive diagnostic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Radiation-emitting products > Nuclides > Lutetium > 177Lu +[4]

Mechanisms of ActionAnti-PTK7Wnt signalling pathway modulators

TargetsProtein-tyrosine kinase 7

Therapy Area/IndicationsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRadiopharm Theranostics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesRadiopharm Theranostics Ltd

Inactive CompaniesN/A

Active IndicationsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A